SBIR-STTR Award

Advanced Sample Processing Platforms for Downstream Single-Cell Multi-Omic Analysis
Award last edited on: 4/26/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$399,761
Award Phase
1
Solicitation Topic Code
439
Principal Investigator
Qi Zhao

Company Information

Enrich Therapeutics Inc

100 Barber Avenue
Worcester, MA 01606
   (203) 815-0259
   inquiry@enrichtx.com
   www.enrichtx.com
Location: Single
Congr. District: 02
County: Worcester

Phase I

Contract Number: 75N91022C00061
Start Date: 9/19/2022    Completed: 9/18/2023
Phase I year
2022
Phase I Amount
$399,761
The long term goal of this proposal is to develop a fast, hands-free platform that integrates tissue dissociation, clone characterization and isolation to support the growing field of single celll multiomics. During the phase I of the proposal, enrich will adapt the exiting image based, debris-resistant clone isolation machine by developing essential reagents, protocols and consumables for in-place tissue dissociation, multicriteria single cell isolation and lossless single cell retrieval. Efficiency of tissue digestion, single cell capture, washing and retrieval will be tightly monitored by existing real-time imaging functionality. Adequate and high viability single cells from human liver and pancreas tumors will be isolated and scRNA and scDNA sequencing libraries of each sample will be prepared by 10xGenomics platform and submitted for Illumina sequencing. The validation will be achieved by an array of metrics including total operation time, level of manual intevention, single cell yield and quality and sc sequence mappability. if successful, a multi-site, tumor type study will be performed in the next phase.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----